Corporate Overview

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.


Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

Natera aims to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 200 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California.

Why Natera?

Validation and Evidence

We validate our tests with clinical studies and make findings publicly available.


peer-reviewed publications

Quality and Accuracy

We meet or exceed applicable industry and regulatory standards for all our tests.


CAP-accredited laboratories

Support and Transparency

We provide expert support to help make our test results clear and easy to understand.


patient/provider support sessions annually

Latest News

Latest Presentation

Upcoming Events

View All Events

Latest Quarterly Reports

View All Reports